Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDV-Insulin Lispro Dose Response in T1D
NCT05689424Phase 1Not yet recruiting
- Sponsor
- University of California, San Diego
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 1, randomised, double-blind trial of HDV-Insulin Lispro in type 1 diabetes mellitus (T1D) (4 arms), sponsored by University of California, San Diego. Primary endpoint: Percentage of suppression of endogenous glucose production. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
HDV-Insulin Lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05689424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689424.